A current challenge of medicine is to bring advances in genomics into the clinic to better tailor treatments to individual patients. The Pharmacogenomics program identifies genomic changes that affect adverse effects and treatment efficacy, and aims to more effectively identify patients who will respond particularly well to specific drug therapies and also to identify those who may experience greater side effects. We also develops genome-based and metabolomic biomarkers to better understand cancer biology, identify individuals at risk of cancer recurrence and novel drug targets. This translational and multidisciplinary research will thus lead to a deeper understanding of the molecular mechanism associated with drug response and cancer progression and contribute to the development of new therapeutic approaches based on individual patient and disease profiles. Findings will contribute to the basis for providing personalised cancer therapy, and it has clearly the potential to improve drug treatments for Canadians.